Why the study?
Recent ACC/AHA and VA guidelines for primary prevention of CVD with statins differ regarding advanced testing to modify 10-year risk estimates and LDL cholesterol targets.
Do statins reduce the risk for cardiovascular disease in patients without known cardiovascular disease?
Do statins reduce the risk for cardiovascular disease in patients without known cardiovascular disease?
This expert discussion highlights different guideline approaches (ACC/AHA vs. VA) to statin therapy and risk assessment for the primary prevention of cardiovascular disease.
Statins reduce primary CVD risk; leaves open optimal risk assessment and LDL targets amid differing guidelines.
Cardiovascular disease (CVD) is the leading cause of death in the United States. Hypercholesterolemia is a principal modifiable risk factor for the primary prevention of CVD. In addition to lifestyle modification, statins are an important tool to reduce risk for CVD in selected patients. A useful strategy to identify candidates for statins is to estimate the 10-year risk for CVD through the use of a validated risk calculator. Commonly used calculators include the Framingham risk score and the pooled cohort equation. Multiple randomized controlled trials have shown that statins reduce the risk for CVD in patients without known CVD. Two recent guidelines have proposed an approach to the use of statins in primary prevention of CVD. The American College of Cardiology/American Heart Association and the U.S. Department of Veterans Affairs guidelines form the basis for this discussion. The guidelines differ on the use of advanced testing to modify the 10-year CVD risk estimate and on the need for low-density lipoprotein cholesterol targets to establish the efficacy of statins. Advanced testing with coronary artery calcium measurement may be helpful for patients who are potentially eligible for statin therapy but who are uncertain if they wish to take a statin. In this paper, 2 experts, a preventive cardiologist and a general internist, discuss their approach to the use of statins for primary prevention of CVD and how they would apply the guidelines to an individual patient.
No takes yet. Share an insight, caveat, or question.
Smetana et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: